Efficacy and safety of peginterferon beta-1a (CinnaGen) versus CinnoVex® (CinnaGen) in reducing the annualized relapse rate (ARR) in participants with relapsing-remitting multiple sclerosis: A phase III, randomized, parallel, non-inferiority study.

Trial Profile

Efficacy and safety of peginterferon beta-1a (CinnaGen) versus CinnoVex® (CinnaGen) in reducing the annualized relapse rate (ARR) in participants with relapsing-remitting multiple sclerosis: A phase III, randomized, parallel, non-inferiority study.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs Peginterferon beta-1a (Primary) ; Peginterferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors CinnaGen
  • Most Recent Events

    • 11 Oct 2018 Planned number of patients changed from 152 to 168.
    • 22 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 09 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top